Ledger.Open graph →
SEC Form D · filed March 24, 2021

Inflammatix, Inc

Offering
$102.4M
Sold
$102.4M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
BURLINGAME, CA
Type

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (17)

Timothy Sweeney · BURLINGAME, CAExec · DirectorKenneth Bahk · BURLINGAME, CADirectorDavid Persing · BURLINGAME, CADirectorSteven Tablak · BURLINGAME, CADirectorMichael Rubin · BURLINGAME, CADirectorSC Management LLC Management SC Management SC SC Management LLC · New York, NYExec · DirectorJason M. Stein · Brooklyn, NYDirectorKyle White · Salt Lake City, UTDirectorAusten Helfrich · Salt Lake City, UTDirectorSC Management LLC Management SC Management SC Management LLC · New York, NYDirectorJustin Kao · San Francisco, CADirectorThejas Nalval · Hoboken, NJExec · DirectorAcies Management LLC · Markham, ILDirectorJingjing Zhang · Markham, ILDirectorNed Mahic · Markham, ILDirectorArnold Kozys · Markham, ILDirectorJustin Kao · San Francisco, CADirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗